| Drug Type Antibody fusion proteins | 
| Synonyms- | 
| Action inhibitors, modulators | 
| Mechanism EBOV glycoprotein inhibitors(EBOV glycoprotein inhibitors), GPC3 inhibitors(Glypican-3 inhibitors), IL-10 modulators(Interleukin-10 modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | United States  | 22 Feb 2024 | 






